1-4 of 4
Sarah Noor
Close
Sort by
Journal Articles

Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability

Brittney Munayirji, Niloufer Khan, Patricia Myskowski, Shamir Geller, Sarah Noor, Meenal Kapoor Kheterpal, Theresa Davey, Helen Hancock, Leslie Perez, Tayler Miller, Jamila Brutus, Nivetha Ganesan, Tiffany Chang, Gianna Mangiaracina, Richa Patel, Natasha Galasso, Ellie Casper, Paola Ghione, Robert Stuver, Zachary D. Epstein-Peterson, Melissa Pulitzer, Michael S. Khodadoust, Youn H. Kim, Steven M. Horwitz, Alison Moskowitz
Journal: Blood
Blood (2023) 142 (Supplement 1): 1702.
https://doi.org/10.1182/blood-2023-184898
Published: 2023
Journal Articles

Primary Cutaneous Peripheral T-Cell Lymphoma, Not Otherwise Specified: Characterization of a Large Cohort with Long-Term Outcomes Shows Disparate Outcomes By Body Region Involvement

Robert Stuver, Paola Ghione, Nivetha Ganesan, Sarah Noor, Brandon S. Imber, Melissa Pulitzer, Steven M. Horwitz
Journal: Blood
Blood (2022) 140 (Supplement 1): 6556–6557.
https://doi.org/10.1182/blood-2022-165489
Published: 2022
Journal Articles

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Clinical Trials & Observations
Alison J. Moskowitz, Paola Ghione, Eric Jacobsen, Jia Ruan, Jonathan H. Schatz, Sarah Noor, Patricia Myskowski, Santosha Vardhana, Nivetha Ganesan, Helen Hancock, Theresa Davey, Leslie Perez, Sunyoung Ryu, Alayna Santarosa, Jack Dowd, Obadi Obadi, Lauren Pomerantz, Nancy Yi, Samia Sohail, Natasha Galasso, Rachel Neuman, Brielle Liotta, William Blouin, Jeeyeon Baik, Mark B. Geyer, Ariela Noy, David Straus, Priyadarshini Kumar, Ahmet Dogan, Travis Hollmann, Esther Drill, Jurgen Rademaker, Heiko Schoder, Giorgio Inghirami, David M. Weinstock, Steven M. Horwitz
Journal: Blood
Blood (2021) 138 (26): 2828–2837.
https://doi.org/10.1182/blood.2021013379
Published: 2021
Includes: Supplemental data
Journal Articles

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Alison J. Moskowitz, MD, Paola Ghione, MD, Eric D Jacobsen, MD, Jia Ruan, MD PhD, Jonathan H. Schatz, MD, Sarah Noor, MD, Patricia Myskowski, Helen Hancock, ANP, Theresa Davey, MMSc, PA-C, Obadi Obadi, Carlissa Onwasigwe, MPH, Nivetha Ganesan, MPH, Lauren Pomerantz, BS, Christine Jarjies, MS, Priyadarshini Kumar, Allison Sigler, Mark B. Geyer, MD, Ariela Noy, MD, David J. Straus, MD, Travis Hollmann, MD, Ahmet Dogan, MD PhD, Natasha Galasso, Giorgio Inghirami, MD, David M. Weinstock, MD, Steven M. Horwitz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4019.
https://doi.org/10.1182/blood-2019-125017
Published: 2019